# APPENDIX V: INTERVIEW SCHEDULE IN PICTORIAL ANNOTATION FORMAT

## Candidate Number: [Insert Candidate Number]

## Date: [Insert Date]

### A: Demography & Estimates:

1. **Tell us about yourself** (Practicing since when; where).
2. **See pharmaceutical reps often & is this valuable?** (Involved in clinical trials?)
3. **Background information of RA patients:**
   - Type of RA patients on TNF-inhibitors (estimated % on TNF-inhibitors; estimated % are juvenile; estimated % have comorbidities: DM, COPD, Asthma; estimated on concomitant immuno-suppressants?)

### B: Systems:

1. **Biologics Register:**
   - your opinion of the Biologics registry, does it work for you?
   - System adequate for monitoring TB associated with TNF-I’s?
   - would the register cater for risk management of TB (if used on large scale in public sector) or would the TB go out of control?
2. **Two separate systems for safety monitoring** (Biologics Register & NADEMC).
   - Duplication of work? Linking of 2 systems?
3. **Patient counselling** - how well informed are patients on the side-effects of TNF-inhibitors and what is there level of understanding?

### C: Prescreening TB

1. **From SAARA’s guidelines is there any situation where you feel prescreening is not important?**
2. **TB Tests:**
   - Preference for a specific TB test? In specific situations (BCG, immunosuppressants, etc)? Why?
   - What is your opinion of the 2 step PPD test?
3. **Rescreening:**
   - Do you feel it is necessary to rescreen? Why? When?
4. **Provide an estimate number of person that tested positive for TB per 100 patients (For both LTBI and Active TB)?**
5. **Protocol:**
   - What protocol do you follow if LTBI or Active TB is detected?
6. **TNF-Inhibitor:**
   - For patients that tested +ve, specific TNF-Inhibitor preferred?

### D: Active TB

1. **Any patients developed active TB whilst on therapy? Please provide details?**
   - Time to diagnosis from initiation of therapy
   - Type of RA patient(s) – see question A.3,
   - Tested +ve for LTBI or active TB during prescreening,
   - What protocol is followed?
2. **Provide an estimate number of person that tested positive for active TB per 100 patients (whilst on r therapy)?**
3. **Restarting TNF inhibitor therapy:**
   - What informs this decision (Patient’s agreement; Severity of disease, etc)
   - Protocol followed in this situation? (When is therapy started; rescreening for TB; preference of TNF inhibitor?)
4. **Are patients surprised or upset when they are informed that they have TB and how do you handle the situation?**